{"title":"侏罗纪医疗系统中的星链药物——我们准备好了吗?","authors":"Tay Salimullah","doi":"10.1089/crispr.2025.0042","DOIUrl":null,"url":null,"abstract":"<p><p>Genomic medicines are transforming the landscape of human health-but their promise risks being confined to the few. While science has entered the 21<sup>st</sup> century, most health systems remain unequipped to deliver one-time curative therapies. This essay calls for a global reckoning: what do we truly value in innovation, and how can we align systems, incentives, and ethics to democratize access? Drawing on real-world experience across four continents, it argues for a new social compact-embedding equity, rethinking value, and modernizing delivery-to ensure that the miracles of modern medicine become global, sustainable, and just.</p>","PeriodicalId":54232,"journal":{"name":"CRISPR Journal","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Starlink Medicines in Jurassic Healthcare Systems-Are We Ready?\",\"authors\":\"Tay Salimullah\",\"doi\":\"10.1089/crispr.2025.0042\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Genomic medicines are transforming the landscape of human health-but their promise risks being confined to the few. While science has entered the 21<sup>st</sup> century, most health systems remain unequipped to deliver one-time curative therapies. This essay calls for a global reckoning: what do we truly value in innovation, and how can we align systems, incentives, and ethics to democratize access? Drawing on real-world experience across four continents, it argues for a new social compact-embedding equity, rethinking value, and modernizing delivery-to ensure that the miracles of modern medicine become global, sustainable, and just.</p>\",\"PeriodicalId\":54232,\"journal\":{\"name\":\"CRISPR Journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CRISPR Journal\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1089/crispr.2025.0042\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CRISPR Journal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/crispr.2025.0042","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
Starlink Medicines in Jurassic Healthcare Systems-Are We Ready?
Genomic medicines are transforming the landscape of human health-but their promise risks being confined to the few. While science has entered the 21st century, most health systems remain unequipped to deliver one-time curative therapies. This essay calls for a global reckoning: what do we truly value in innovation, and how can we align systems, incentives, and ethics to democratize access? Drawing on real-world experience across four continents, it argues for a new social compact-embedding equity, rethinking value, and modernizing delivery-to ensure that the miracles of modern medicine become global, sustainable, and just.
CRISPR JournalBiochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.30
自引率
2.70%
发文量
76
期刊介绍:
In recognition of this extraordinary scientific and technological era, Mary Ann Liebert, Inc., publishers recently announced the creation of The CRISPR Journal -- an international, multidisciplinary peer-reviewed journal publishing outstanding research on the myriad applications and underlying technology of CRISPR.
Debuting in 2018, The CRISPR Journal will be published online and in print with flexible open access options, providing a high-profile venue for groundbreaking research, as well as lively and provocative commentary, analysis, and debate. The CRISPR Journal adds an exciting and dynamic component to the Mary Ann Liebert, Inc. portfolio, which includes GEN (Genetic Engineering & Biotechnology News) and more than 80 leading peer-reviewed journals.